baber/WOPTO huggingface dataset:
Patent MX-155664-A (MX)
Inventor: UPHOLD JAMES D
IPC: A61B1/00
Filed: 1984-08-10
Abstract: A patient vital signs monitoring system includes an elongated flexible esophageal stethoscope catheter including a mircophone and a thermister measuring means detachably connected to a processing monitor through a patient interface unit for electrical isolation of the patient from the processing system to assure patient safety from electrical currents. A single microphone, including an amplifier, picks up and transmits sound from the stethoscope catheter through a processing system including an audio filter system in the patient interface unit which filters out unwanted sounds and selectively amplifies either one or both of the heartbeat and breathing sounds and transmits signals indicative of these sounds to the monitor/transmitter unit through a fiberoptic link to the microprocessor where the signals are converted into counts per units of time (rates), which are, in turn, compared against reference upper and lower limits for generating alarm signals in response to critical deviations from preset norm. The monitor/transmitter unit is programmed to be self-monitoring by running initial tests of the system prior to going into the normal patient monitoring mode and by a continuous monitoring submode while in the monitoring mode. An IR transmitter in the monitor/transmitter unit transmits the vital breath and heart sounds by way of an infrared signal which is picked up by receiver carried by the operator and monitored by an earphone to eliminate interference from electrical systems and avoiding additional hardline electrical connection within the operating room. A self-destruct circuit within the patient interface unit destroys the microphone circuit within the esophageal stethoscope catheter during disconnect of the catheter in order to prevent reuse of the esophageal catheter.
Patent NZ-201660-A (NZ)
Title: Optically uniform beta-lactams
Inventor: HUBSCHWERLEN C N
IPC: C07D317/36
Filed: 1982-08-20
Abstract: There is presented optically uniform  beta -lactams of the formulae <IMAGE>   wherein Z is a readily cleavable acyl group, R1 is amino or a group convertible into amino, R2 is hydrogen or a readily cleavable protecting group and R3 and R4 each are a lower hydrocarbon group which optionally contains oxygen and which is attached via a carbon atom, whereby these groups can also be joined with one another to form a ring, with the proviso that R1 is a readily cleavable acylamino when R2 is hydrogen, and the corresponding optical antipodes, their manufacture and use in the manufacture of antimicrobially-active  beta -lactams as well as novel intermediates usable in their manufacture.
Patent NZ-211056-A (NZ)
Title: Making blown polyethylene film
Inventor: VAN DER MOLEN T J
IPC: B29C48/10
Filed: 1985-02-05
Abstract: Blown film on the basis of low-density polyethylene is prepared by extruding the molten polymer at melt temperatures at the die gap of below 135 DEG C. Films that have been prepared this way have special orientation as a result of which good mechanical and optical properties are present. Oriented films are determined by X-ray diffraction analysis and have an intensity ratio of the 110 reflection band max./min. of at least 20, and an angle  alpha between the average orientation direction of the polymer molecules and the film extrustion direction of at most 20 DEG .
Patent NZ-225030-A (NZ)
Title: Composite sample container and testing device for body fluids
Inventor: NUGENT E L
IPC: B01L3/00
Filed: 1988-06-15
Abstract: A composite body fluid sample container is provided which incorporates at least one dry chemistry test strip into the structure with a shrink-wrap film whereby a plurality of chemically impregnated patches are exposed simultaneously in a self-contained device to provide instant response to a specimen introduced into the container. Moreover, the device separates the test strip from the remainder of the specimen so as to provide for additional testing if required. In addition, the device maintains the specimen, and the impregnated test strip isolated from exposure to contamination while at the same time keeping the specimen, if diseased, from contaminating handlers of the device. Finally, the device protects against breakage and any resulting leakage or contamination.
Patent NZ-229428-A (NZ)
Title: Heating matter using combustible gaseous mixture at elevated temperature for spontaneous ignition
Inventor: DODSON CHRISTOPHER EDWARD
IPC: F23C10/00
Filed: 1989-06-06
Abstract: A method of heating matter comprises supplying a gaseous mixture, which is reactable to produce heat, at a temperature above that at which spontaneous ignition occurs to a heating zone such that the gaseous mixture reacts to provide a heated fluid flow in said heating zone, and supplying matter to be heated to said heating zone.
Patent NZ-235828-A (NZ)
Title: Blanching or cooking pasta strands and apparatus therefor
Inventor: LARSEN HANS KURT
IPC: A23L5/10
Filed: 1990-10-25
Abstract: A blanching tank (16) having positioned therein at least one substantially stationary roller (19) and at least one movable roller (22) capable of reciprocating vertically from a position above to a position below the substantially stationary roller (19).
Patent NZ-244841-A (NZ)
Title: Gas delivery system for gas fuelled i.c. engine using pre-combustion chamber to initiate ignition
Inventor: NEUMANN BARRY RICHARD
IPC: F02B19/10
Filed: 1992-10-21
Abstract: PCT No. PCT/AU92/00575 Sec. 371 Date Nov. 21, 1994 Sec. 102(e) Date Nov. 21, 1994 PCT Filed Oct. 23, 1992 PCT Pub. No. WO93/08399 PCT Pub. Date Apr. 29, 1993A gas delivery system for gas fuelled internal combustion engines, comprising a gas fuel delivery means for delivering a controlled amount of gaseous fuel to a region adjacent a source of ignition. The gas fuel delivery means comprises first and second delivery means for delivering gaseous fuel to a pre-combustion zone and a combustion zone respectively. Gas control means control the relative proportions of gaseous fuel delivered by the first and second delivery means respectively so that combustion in the combustion zone can be achieved with minimum gaseous fuel by initiating ignition of gaseous fuel in the pre-combustion zone. Thus, the fuel/air ratio within the combustion zone can be minimized (lean burn regime) without the onset of engine misfire.
Patent NZ-253002-A (NZ)
Title: Cosmetic containing fluorocarbon (for carrying oxygen to the skin) and asymmetric lamellar aggregate of phospholipid
Inventor: GROSS UDO
IPC: A61K8/00
Filed: 1993-06-24
Abstract: A cosmetic is disclosed for aiding the transport of oxygen in the skin, as well as a process for preparing the same and its use. The problem with known cosmetics is the insufficient oxygen supply to the skin and adjacent tissues. The object of the invention provides a means to go beyond the stratum corneum of the skin and the epiderm by penetration processes in order to increase the oxygen concentration in the corial zone and adjacent tissues and to activate the metabolic processes. For that purpose, a cosmetic with asymmetrical lamellary aggregates consists of phospholipids and an oxygen-loaded fluorocarbon compound or a fluorocarbon compound mixture. The proportion of fluorocarbon compound lies in a range from 0.2 to 100 % by weight/volume, and it is contained in an excipient appropriate for dermatological uses. This cosmetic is prepared by emulsifying its components and is used in salves, creams, lotions, liquids, alcoholic extracts, pastes, powders, gels, tinctures on or plasters and bandages, or in a spray.
Patent NZ-273952-A (NZ)
Title: Copolymer of n-(2-hydroxypropyl)methacryloylamide and n-methacryloylglycine derivative having camptothecin bound through a spacer to some of the glycine residues
Inventor: ANGELUCCI FRANCESCO
IPC: A61K47/48
Filed: 1994-09-21
Abstract: PCT No. PCT/EP94/03154 Sec. 371 Date Jun. 8, 1995 Sec. 102(e) Date Jun. 8, 1995 PCT Filed Sep. 21, 1994 PCT Pub. No. WO95/10304 PCT Pub. Date Apr. 20, 1995A polymeric conjugate consists essentially of: (i) from 60 to 99 mol % of N-(2-hydroxypropyl) methacryloylamide units represented by formula 1:  ethacryloylglycyl-aminoacyl) camptothecin units represented by formula 2    <IMAGE>  2  wherein [A] is a spacer group having respective terminal amino and carbonyl groups which are separated by at least three atoms and O-CPT represents a residue of a camptothecin, the C-20 hydroxy group of the camptothecin being linked to the terminal carbonyl group of the spacer group [A]; and (iii) from 0 to 10 mol % of N-methacryloylglycine or N-(2-hydroxy-propyl)methacryloylglycinamide units represented by formula 3:    <IMAGE>  3  wherein Z represents hydroxy or a residue of formula -NH-CH2-CH(OH)-CH3.
Patent NZ-275151-A (NZ)
Title: 3r*4s*3-[4-(4-fluorophenyl)-4-hydroxy-piperidin-1-yl]-chroman-4 ,7-diol; isomers and salts
Inventor: BUTLER TODD W
IPC: A61K31/445
Filed: 1994-11-21
Abstract: PCT No. PCT/IB94/00365 Sec. 371 Date Oct. 24, 1996 Sec. 102(e) Date Oct. 24, 1996 PCT Filed Nov. 21, 1994 PCT Pub. No. WO95/20587 PCT Pub. Date Aug. 3, 19953R*4S*3-[4-(4-fluorophenyl)-4-hydroxy-piperidin-1-yl]-chroman-4,7-diol, its enantiomers and pharmaceutically acceptable salts are effective oral agents for treating diseases and conditions susceptible to treatment by NMDA blocking drugs.
Patent NZ-278667-A (NZ)
Title: Use of isoxazoline derivatives to inhibit TNF production
Inventor: COHAN VICTORIA L
IPC: C07D261/04
Filed: 1995-02-03
Abstract: Isoxazoline derivatives of formula (I) or racemic, racemic-diastereoisomers mixtures, optical isomers or pharmaceutically acceptable salts are used in the manufacture of a medicament for: - inhibiting production of tumour necrosis factor (TNF) or - treating or alleviating sepsis, septic shock, inflammatory bowel disease, tuberculosis, graft versus host disease or cachexia associated with AIDS or cancer or - treating or alleviating an inflammatory disease or condition chosen from rheumatoid arthritis, osteoarthritis, asthma, bronchitis, chronic obstructive airways disease, psoriasis, allergic rhinitis, or dermatitis in a mammal in need thereof. In formula (I): X1 is -(CH2)qOH or -CHOHR5 or -(CH2)mN(R6)(OH); q and m are independently 0 to 5; R5 is alkyl; R6 is H or alkyl; n is 0, 1, 2 or 3; Y1 and Y2 are independently hydrogen, alkyl, optionally substituted phenylalkyl, optionally substituted phenoxyalkyl, cycloalkyl, difluoromethyl, trifluoromethyl, fluoro, chloro, bromo, iodo, -OR1 or -OR2; R1 is alkyl, phenylalkyl,  fluoromethyl, difluoromethyl, trifluoromethyl or -(CH2)r-quinoline; r is 0 to 5; R2 is alkyl, cycloalkyl, alkoxyalkyl, optionally substituted phenoxyalkyl, optionally substituted phenylalkyl, bicycloalkyl or optionally substituted indanyl; R3 is hydrogen, alkyl, fluoroalkyl, hydroxyalkyl or alkoxyalkyl; R4 is hydrogen, alkyl, fluoroalkyl, hydroxyalkyl, phenyl, alkoxyalkyl, aminoalkyl, -(CH2)t-NH-C(O)-X2, N-alkylaminoalkyl, cycloalkyl or N,N-dialkylaminoalkyl or R3 and R4 together with the carbon atoms to which they are attached form a carbocyclic ring; X2 is alkyl and t is 1 to 3. A pharmaceutical composition containing the above defined compounds of formula I provided that X1 is not -(CH2)mN(R6)(OH) when m is 0, 1, 2 or 3 and R1 is C1-4 alkyl unless Y1 is (CH2)r-quinoline and r is 0, 4 or 5 is useful in inhibiting tumour necrosis factor in a mammal.
Patent NZ-284064-A (NZ)
Title: Sustained-release matrix pellets containing a water-insoluble polymer and a lipophilic plasticiser
Inventor: GRABOWSKI SVEN
IPC: A61K9/16
Filed: 1995-04-05
Abstract: Slow-release matrix pellets with a spherical or lenticular shape and uniform maximum diameters in the range from 0.5 to 4 mm, composed ofa) 0.1-87% by weight of at least one biologically active compound,b) 5-50% by weight of at least one water-insoluble polymer,c) 5-45% by weight of at least one lipophilic component as plasticizer for polymer b),d) 3-40% by weight of a natural or semisynthetic gel former,e) 0-50% by weight of one or more conventional formulation aids.
Patent NZ-314112-A (NZ)
Title: Preparation of allo-inositol by reduction of d-chiro-inosose
Inventor: HUDLICKY TOMAS
IPC: C07D493/04
Filed: 1993-09-23
Abstract: There are described novel biocatalytic and chemical processes for the synthesis of various oxygenated compounds. Particularly, there are described processes for the synthesis of a useful synthon (12) made by reacting a protected diol (acetonide) with permanganate under appropriate conditions. Such synthon is useful of the synthesis of various pharmaceutically important compounds such as D-chiro-inositol and D-chiro-3-inosose. Also, there are disclosed novel compounds, including specifically the synthon (12) and compounds derived therefrom.
Patent NZ-315984-A (NZ)
Title: Polymers with fractal structure
Inventor: LEFEBVRE MICHEL SERGE MAXIME
IPC: C08F2/00
Filed: 1996-09-04
Abstract: The polymer has a fractal configuration or structure which is homogenous and self-similar and is strictly scale invariant at different scales.  The polymer structure has a fractal or Hausdorff dimension d which is not an integer, according to the Mandelbrot equation: Nhd = constant (lod) where h is a gauge or measure, N is the count obtained by measuring the medium with the gauge h, lo is the characteristic length and d is the Hausdorff (fractal) dimension (dER).  The polymer is prepared by making the base polymer by mixing and polymerisation of monomers; spinning and drawing the base polymer at very high drawing ratio to obtain a highly crystalline structure in the base polymer; mixing of the base crystalline polymer with a liquid reagent to break hydrogen bonds in the polymer for step-by-step unfolding of the polymer miscelle; and coagulation, film forming or extrusion of the polymer.
Patent NZ-315995-A (NZ)
Title: Artificial sintered composition comprising stabilised calcium phosphate phases capable of supporting bone cell activity
Inventor: PUGH SYDNEY M
IPC: C04B41/87
Filed: 1996-08-30
Abstract: The present invention is directed to a synthetic biomaterial compound based on stabilized calcium phosphates and more particularly to the molecular, structural and physical characterization of this compound. The compound comprises calcium, oxygen and phosphorous, wherein at least one of the elements is substituted with an element having an ionic radius of approximately 0.1 to 1.1 Å. The knowledge of the specific molecular and chemical properties of the compound allows for the development of several uses of the compound in various bone-related clinical conditions.
Patent NZ-332075-A (NZ)
Title: Decontamination of rpet through particle size reduction
Inventor: HAYWARD DONALD W
IPC: B29C35/02
Filed: 1997-03-31
Abstract: Comtaminants are removed from RPET flakes by a process which includes the steps of comminuting the RPET flakes to produce RPET particles and driving the contaminants out from the RPET particles.
Patent NZ-332488-A (NZ)
Title: Vitamin D derivatives with carbo- or heterocyclic substituents at c-25, a process for their production, intermediate products and their use for producing medicaments
Inventor: STEINMEYER ANDREAS
IPC: C07C401/00
Filed: 1997-04-21
Abstract: Vitamin D derivatives with carbo or heterocyclic substituents at C-25 of the formula 1 where Y1 is hydrogen, OH, alkanoyloxy group with 1-12 C atoms or an aroyloxy group, Y2 is H or alkanoyl group with 1-12 C atoms or an aroyl group R1 and R2 are H or together an exocyclic methylene group, R3 and R4 are H, chlorine, fluorine, alkyl of C1-4, together a methylene group or together with quaternary carbon atom 20 a 3-7 membered, saturated or unsaturated carbocyclic ring, means a straight chain or branched carbon unit with up to 10 carbon atoms, which at any positions can have OH groups in a or b position, which in turn can be etherified or esterified, keto groups, amino groups or halogen atoms R5 and R6 are H, chlorine, fluorine, with quaternary carbon atom 25 a 3-7 membered, saturated or unsaturated carbocyclic ring, means a straight chain or branched carbon unit Z is a five or six membered carbo- or heterocyclic ring, which can be saturated, unsaturated or aromatic, and at any positions one or more alkyl chains which can be straight or branched, saturated or unsaturated and at any points can be interrupted by oxa, thia, aza groups or sulfoxide or sulfo groups. These derivatives are used for therapy of hypercalcemia (hypervitaminosis D, intoxication with calcitriol or its analogs).
Patent NZ-334831-A (NZ)
Title: Retainer with portions to prevent hinged container lid from opening past predetermined position, and to prevent lid from subsequent closing
Inventor: WHAREWERA WALTER TAPUARIKI
IPC: B65D43/24
Filed: 1999-03-25
Abstract: Retainer 1 is typically located between lip 11 and hinge 12 of a wheeled rubbish bin. Portion 5 (of retainer 1) prevents the lid 13 from opening past a certain point, and portion 6 (when moved as shown) prevents the lid from closing.
Patent NZ-508365-A (NZ)
Title: Fuel lubricity additives
Inventor: WILLIAMSON WILL F
IPC: C10L1/196
Filed: 1999-05-26
Abstract: A fuel lubricity additive compound which comprises an intermediate adduct of a first moiety reacted in a first reaction with a second moiety to form the intermediate adduct. The intermediate adduct is esterifying or amidifying with a third moiety in a molar ratio from 1:2 to about 2:1. The first moiety is an unsaturated triglyceride plant oil or a thermal polymer thereof. The second moiety is a diene or conjugate double bond acid or anhydride moiety. The first reaction comprises mixing the first moiety with the second moiety in a molar ratio from 1:2 to 2:1, at a temperature from about 130 to 195oC under an inert atmosphere. The third moiety is a polyhydroxy or a polyamino compound. The fuel lubricity additive compound may be added to diesel fuel and kerosene that provides lubricity properties, improved combustion and improved emissions characteristics.
Patent NZ-513404-A (NZ)
Title: Iontophoresis, electroporation and combination patches for local drug delivery
Inventor: BROWN CHARLES L
IPC: A61N1/30
Filed: 2000-02-10
Abstract: Patch-based devices for enhancing the local delivery of drugs, pharmaceuticals, plasmids, genes, and other agents into the tissues (260) of the living body. The patch devices provide an electrical driving force that can increase the rate of migration of drugs and other therapeutic agents out of a polymer matrix into body tissues and cells using iontophoresis only, electroporation only, or combined iontophoresis and electroporation. The two procedures may be applied sequentially in any order without removing or repositioning the patch.
Patent NZ-523000-A (NZ)
Title: Pharmaceutical compositions comprising acryloyl distamycin derivatives and topoisomerase I and II inhibitors
Inventor: GERONI MARIA CRISTINA ROSA
IPC: A61P35/00
Filed: 2001-06-20
Abstract: Disclosed are pharmaceutical compositions comprising an acryloyl distamycin derivative of formula (I), wherein: R1 is bromine or chlorine, and R2 is a group of formula (II), wherein m is 0, n is 4, r is 0, X and Y are both CH and B is a group of formula (III), wherein R5, R6 and R7 are independently H or alkyl; and an antineoplastic topisomerase inhibitor of type I or II.
Patent NZ-524784-A (NZ)
Title: Improved quilting ruler
Inventor: TANDY RACHEL CLAIRE
IPC: D05B97/12
Filed: 2001-09-25
Abstract: A quilting ruler (10) is square or rectangular in shape and has first, second, third and fourth edges (2, 4, 6, 8), with a first set of equally spaced rulings running (12) parallel to the first and third edges (2, 6) of the ruler and at right angles to a second set of equally spaced rulings (14) running parallel to the second and fourth edges (4, 8) of the ruler.  The first line of the first set of rulings is spaced from the first edge (2) of the ruler by a different interval from the interval by which the last line of that set of rulings is spaced from the third edge (6) of the ruler, and the distance of each line of the first set of rulings from the first edge and of each line of the second set of rulings from the second edge is marked so as to be visible when the first and second edges of the ruler are in use and the distance of each line of the first set of rulings from the third edge and of each line of the second set of rulings from the fourth edge is marked so as to be visible when the third and fourth edges of the ruler are in use.
Patent NZ-525666-A (NZ)
Title: Visual and scene graph interfaces for a graphics application
Inventor: BEDA JOSEPH
IPC: G06F9/44
Filed: 2003-05-02
Abstract: In a computing environment a method comprises: receiving a request to create a visual to contain graphic information in a scene graph at the defined interface and creating a visual in response; providing a drawing context for the visual such as a request to open the visual and in response providing a reference to the drawing context; maintaining data in association with the visual such as maintaining at least one drawing primitive with the data being received via the drawing context and processing the scene graph including the visual to provide graphics data to a graphics subsystem. The method can further comprise receiving a request to close the drawing context and closing the drawing context in response. A computer-implemented method comprises receiving function calls at an interface to a scene graph data structure and processing data associated with the function calls to create objects with respect to one another with the objects corresponding to a scene graph object model. The object can be a validation visual where a program is called to repopulate the validation visual or the object can comprises a visual further providing a drawing context to populate the object with drawing data received via the drawing context.
Patent NZ-529593-A (NZ)
Title: A coupling
Inventor: DAGG HAYDEN
IPC: E04B7/00
Filed: 2003-11-17
Abstract: A coupling for purlin to rafter or girt to upright. The coupling comprising a rafter/ upright member adapted for selective location along the rafter or upright. A purlin/girt fixture is connected to the rafter /upright member, the purlin/girt fixture being adapted for securing to or locating on the end of the purlin or girt. Flange means projecting from the end of the purlin/girt fixture enables the connection of the purlin/girt remote end to the rafter or upright.
Patent NZ-531434-A (NZ)
Title: Polynucleotide regulatory sequences that modify expression of endogenous and/or heterologous polynucleotides in transgenic plants
Inventor: PERERA RANJAN
IPC: C12N15/09
Filed: 2001-06-20
Abstract: The polynucleotides disclosed were isolated from forestry plant sources, namely Eucalyptus grandis and Pinus radiata, but they may alternatively be synthesized using conventional synthesis techniques. Specifically, isolated polynucleotides include polynucleotides comprising a sequence selected from the group consisting of 5'UTR sequences identified as SEQ ID NOs: 113-116 and 118-120; complements, reverse complements, reverse sequences and sequences having at least 75-90% identity to the aforementioned polynucleotides. The putative identity of each of the polynucleotides disclosed comprises Caffeic acid O-methyltransferase, UDP glucose glycosyltransferase, UDP glucose 6 dehydrogenase, Laccase 1, Constans, Flowering Promoting Factor 1 (PFP1) and Agarmous. (62) Divided out of 523633
Patent NZ-532415-A (NZ)
Title: Shelf-stable shredded cheese and a method of preparation thereof
Inventor: ABBOUD AMMA MUNJI
IPC: A23C19/09
Filed: 2004-04-20
Abstract: Disclosed herein is a shelf-stable shredded cheese which comprises: (1) natural or process cheese; (2) cheese powder; (3) glycerin; and (4) filler, wherein the shelf-stable shredded cheese has a water activity of less than 0.5, it exhibits significant reduction or elimination of stickiness and rapid skin formation upon melting, and has a shelf life of at least about 3 months at ambient temperatures. A method of preparing shelf-stable shredded cheese is also disclosed.